代谢功能障碍相关脂肪性肝病诊疗进展*

doi:10.3969/j.issn.1672-5069.2024.04.001

Abstract

Chen Sitong, Wei Xiaodie, Wei Xinhuan, et al. Diagnosis and treatment of patients with metabolic dysfunction-associated steatotic liver disease[J]. Journal of Practical Hepatology, 2024, 27(4): 481-483.

References

[1] Riazi K, Azhari H, Charette J H, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2022, 7(9): 851-861.
[2] Harrison S A, Bedossa P, Guy C D, et al. A phase 3, randomized, controlled trial of resmetirom in MASH with liver fibrosis. N Engl J Med, 2024, 390(6): 497-509.
[3] Xia T, Du M, Li H, et al. Association between liver MRI proton density fat fraction and liver disease risk. Radiology, 2023, 309(1): e231007.
[4] Shao C X, Ye J, Dong Z, et al. Steatosis grading consistency between controlled attenuation parameter and MRI-PDFF in monitoring metabolic associated fatty liver disease. Ther Adv Chronic Dis, 2021, 12: 20406223211033119.
[5] Noureddin M, Lam J, Peterson M R, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology, 2013, 58(6): 1930-1940.
[6] Rinella M E, Neuschwander-Tetri B A, Siddiqui M S, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 2023, 77(5): 1797-1835.
[7] Harrison S A, Taub R, Neff G W, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med, 2023, 29(11): 2919-2928.
[8] Kim B K, Tamaki N, Imajo K, et al. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. J Hepatol, 2022, 77(6): 1482-1490.
[9] Tamaki N, Imajo K, Sharpton S, et al. Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of MASH-related fibrosis. Hepatology, 2022, 75(3): 661-672.
[10] Vali Y, Lee J, Boursier J, et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol Hepatol, 2023, 8(8): 714-725.
[11] Younes R, Caviglia G P, Govaere O, et al. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. J Hepatol, 2021, 75(4): 786-794.
[12] Collier A, Curran C, Cameron L, et al. Liver fibrosis markers and all cause mortality in people with type 2 diabetes: A population based study (The Ayrshire Diabetes Outcomes Cohort (ADOC) Study). Diabetes Obes Metab, 2023, 25(9): 2659-2668.
[13] Ajmera V, Kim B K, Yang K, et al. Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease: A systematic review and Meta-analysis of individual participants. Gastroenterology, 2022, 163(4): 1079-1089,e5.
[14] Sanyal A J, Castera L, Wong V W. Noninvasive assessment of liver fibrosis in NAFLD. Clin Gastroenterol Hepatol, 2023, 21(8): 2026-2039.
[15] Siddiqui M S, Yamada G, Vuppalanchi R, et al. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol, 2019, 17(9): 1877-1885,e5.
[16] Hagström H, Talbäck M, Andreasson A, et al. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. J Hepatol, 2020, 73(5): 1023-1029.
[17] Petta S, Sebastiani G, Viganò M, et al. Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. Clin Gastroenterol Hepatol, 2021, 19(4): 806-815,e5.
[18] Stine J G, Munaganuru N, Barnard A, et al. Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: A systematic review and Meta-analysis. Clin Gastroenterol Hepatol, 2021, 19(11): 2274-2283,e5.
[19] Vuppalanchi R, Jain A K, Deppe R, et al. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2014, 12(12): 2121-2130,e1-2.
[20] McGlinchey A J, Govaere O, Geng D, et al. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. JHEP Rep, 2022, 4(5): 100477.
[21] Johnson K, Leary P J, Govaere O, et al. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. JHEP Rep, 2022, 4(2): 100409.
[22] Lee J, Westphal M, Vali Y, et al. Machine learning algorithm improves the detection of MASH (NAS-based) and at-risk MASH: A development and validation study. Hepatology, 2023, 78(1): 258-271.
[23] Hatziagelaki E, Paschou S A, Schön M, et al. NAFLD and thyroid function: pathophysiological and therapeutic considerations. Trends Endocrinol Metab, 2022, 33(11): 755-768.
[24] Bruinstroop E, Zhou J, Tripathi M, et al. Early induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression. Mol Metab, 2021, 53: 101266.
[25] Newsome P N, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med, 2021, 384(12): 1113-1124.
[26] Loomba R, Sanyal A J, Kowdley K V, et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in MASH. N Engl J Med, 2023, 389(11): 998-1008.
[27] Harrison S A, Abdelmalek M F, Neff G, et al. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol, 2022, 7(7): 603-616.
[28] Harrison S A, Alkhouri N, Davison B A, et al. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. J Hepatol, 2020, 72(4): 613-626.
[29] Fraser D A, Harrison S A, Schuppan D. Icosabutate: targeting metabolic and inflammatory pathways for the treatment of MASH. Expert Opinion on Investigational Drugs, 2022, 31(12): 1269-1278.
[30] Syed-Abdul M M, Parks E J, Gaballah A H, et al. Fatty acid synthase inhibitor TVB-2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities. Hepatology, 2020, 72(1): 103-118.

Diagnosis and treatment of patients with metabolic dysfunction-associated steatotic liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liu Yali, Zhang Jing. Child and adolescent metabolic dysfunction-associated fatty liver disease:current state of the art and perspectives [J]. Journal of Practical Hepatology, 2024, 27(4): 488-491.
[2]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease(Version 2024) [J]. Journal of Practical Hepatology, 2024, 27(4): 494-510.
[3]	Xue Lina, Zhu Guobing, Wu Linlin, et al. Virological response to tenofovir alafenamide in patients with low-level viremia chronic hepatitis B after entecavir treatment [J]. Journal of Practical Hepatology, 2024, 27(4): 519-522.
[4]	Luo Hongxia, Li Jingqiu, Li Yuanyuan, et al. Magnetic resonance proton density fat fraction in overweight/obese children with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2024, 27(4): 527-530.
[5]	Ren Hao, Xiong Qingfang. Diagnostic performance of fournoninvasive detection indexes in predicting liver cirrhosis in patients with autoimmune liver diseases [J]. Journal of Practical Hepatology, 2024, 27(4): 535-538.
[6]	Ke Haixia, Zhang Jiaozhen, Meng Xialing, et al. Assessment of bacterial infection by serum CRP and sTREM-1 levels in patients with hepatitis B virus-associated acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2024, 27(4): 555-558.
[7]	Zhao Weibo, Wang Yuan, Kong Lingjia, et al. Effect of balloon-compression endoscopic injection sclerotherapy in the treatment of patients with decompensated stage of hepatitis B cirrhosis and esophageal varices [J]. Journal of Practical Hepatology, 2024, 27(4): 559-562.
[8]	Tang Zeyu, Gu Fei, Zhou Jianwen, et al. Diagnostic efficacy of CT parameters and FIB-4 and serum VEGF levels in predicting esophageal varices in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(4): 579-582.
[9]	Xia Lipeng, Chu Yuxuan, Zhao Rusheng. Contrast-enhanced MRI and IVIM-DWI in the diagnosis of patients with small hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(4): 587-590.
[10]	Tian Chunyan, Luo Li, Cao Xueling, et al. Differential diagnosis of hepatocellular carcinoma and hepatic hemangioma by contrast-enhanced ultrasonography [J]. Journal of Practical Hepatology, 2024, 27(4): 603-606.
[11]	Wang Zhenghua, Wang Mingda, Zhang Xiaoqian. Qualitative diagnosis of hepatic space-occupying lesions by contrast-enhanced ultrasonography [J]. Journal of Practical Hepatology, 2024, 27(4): 607-610.
[12]	Sui Hu, Mao Jia, Chen Lu, et al. Application of CT quantitative parameters in the differentiation of hepatocellular carcinoma from focal nodular hyperplasia [J]. Journal of Practical Hepatology, 2024, 27(4): 611-614.
[13]	Liang Lei, Li Yingdong, Gao Yang, et al. Clinical and imaging feature in patients with focal nodular hyperplasia of the liver [J]. Journal of Practical Hepatology, 2024, 27(4): 615-618.
[14]	Wu Helin, Wu Huihui, Shen Chunlin. Feature of spiral CT multi-phase enhancement of inflammatory pseudotumor of the liver: An analysis of 32 cases [J]. Journal of Practical Hepatology, 2024, 27(4): 623-626.
[15]	He Zhi, Qu Zedong, Liu Jie, et al. Application of magnetic resonance cholangiopancreatography and diffusion-weighted imaging in the diagnosis of infants with biliary atresia [J]. Journal of Practical Hepatology, 2024, 27(4): 631-634.